Glp 1 Glucagon-like peptide-1 (GLP-1) is a fascinating peptide hormone that plays a crucial role in regulating glucose homeostasis and has significant implications for metabolic health. As a key incretin hormone, GLP-1 is released from the intestine in response to food intake and influences blood sugar levels, appetite, and digestion.作者：L Collins·2024·被引用次数：337—Glucagon-like peptide-1 (GLP-1) agonistsare a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity. Its physiological functions have led to the development of GLP-1 receptor agonists, a class of medications that mimic its actions and are widely used in treating type 2 diabetes and obesity. Understanding GLP-1 as a peptide hormone is fundamental to grasping the mechanisms behind these important therapeutic agents.作者：EP Brichtová·2023·被引用次数：31—Glucagon-like peptide 1 (GLP-1) is a 31-amino acid peptide hormone, the analogs of which are frequently used in the treatment of type 2 diabetes ...
GLP-1 is a 30- or 31-amino acid peptide hormone. It is derived from the post-translational processing of proglucagon in the intestinal L-cells.Glucagon-Like Peptide I human = 97 HPLC 87805-34-3 This peptide's structure and function are central to its biological activity.作者：KS Chichura·2023·被引用次数：22—We demonstrate thattwo peptide biased agonists (GEP44 and GEP12) of the GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors (GLP-1R, Y1-R, and Y2-R, ... When food is consumed, particularly carbohydrates and fats, GLP-1 is secreted into the bloodstream. This release is glucose-dependent, meaning it is triggered by elevated blood glucose levels, and it is also stimulated by the presence of nutrients in the gut.Peptide GLP-1 receptor agonists: From injection to oral ...
The primary roles of GLP-1 in the body revolve around metabolic regulation:
* Glucose Homeostasis: GLP-1 stimulates glucose-dependent insulin release from pancreatic beta cellsGlucagon-like peptide 1-based therapies for the treatment .... This means it prompts the pancreas to release insulin only when blood sugar levels are high, thereby helping to lower them. It also suppresses glucagon secretion, another hormone that raises blood sugar, further contributing to glycemic controlGlucagon-like peptide-1 receptor agonists (GLP-1s or GLP-1RAs) are medicines that help people feel fuller by mimicking a natural hormone released after ....
* Appetite Regulation: GLP-1 acts on the brain to promote satiety, making individuals feel fuller for longer.Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI This effect contributes significantly to reduced food intake and appetite suppression.
* Gastric Emptying: GLP-1 slows down the rate at which the stomach empties its contents into the small intestine. This delayed gastric emptying also contributes to a feeling of fullness and can prevent rapid spikes in blood glucose after meals.
* Cardiovascular Effects: Emerging research suggests GLP-1 may have beneficial effects on the cardiovascular system, though this is an area of ongoing investigation.
* Lipid Metabolism: GLP-1 also plays a role in regulating lipid metabolism, impacting processes related to fats in the body.
The discovery of GLP-1's actions paved the way for the development of GLP-1 receptor agonists (GLP-1 RAs). These medications are designed to mimic the effects of the natural GLP-1 peptide but are often engineered for longer duration of action. They are highly effective in managing type 2 diabetes mellitus (T2DM) and have also shown significant efficacy in promoting weight loss.
Prominent examples of GLP-1 receptor agonists include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss), liraglutide (Victoza for diabetes and Saxenda for weight loss), and dulaglutide (Trulicity). These drugs have demonstrated high efficacy in lowering blood sugar levels and improving insulin sensitivity. Their ability to promote weight loss, by reducing appetite and slowing gastric emptying, has made them increasingly popular for individuals struggling with obesity.
While the natural GLP-1 peptide has a very short half-life in the body, making it unsuitable for therapeutic use, synthetic analogs have been developed.作者：EP Brichtová·2023·被引用次数：31—Glucagon-like peptide 1 (GLP-1) is a 31-amino acid peptide hormone, the analogs of which are frequently used in the treatment of type 2 diabetes ... These include various forms of GLP-1 receptor agonists, such as GLP-1 (7-37) and GLP-1 (7-36) amide, which are bioactive truncated forms. The development has also progressed from injectable formulations to oral options, enhancing patient convenience. Furthermore, research is exploring poly-agonist peptides that activate multiple receptors, including GLP-1, to achieve broader therapeutic effectsGlucagon-like peptide 1 aggregates into low-molecular ....
Despite their benefits, GLP-1 receptor agonists can have side effects, including gastrointestinal issues like nausea and vomiting. There have also been rare reports of more serious conditions such as pancreatitisGlucagon-Like Peptide-1: New Regulator in Lipid Metabolism. It is important for patients to be aware of these potential risks and to discuss them with their healthcare providers.Glucagon‐like peptide agonists: A prospective review The field is continuously evolving, with ongoing research into new GLP-1-based therapies, including dual agonists that target both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, aiming for even greater efficacy in managing metabolic diseases. The understanding of GLP-1 as a peptide hormone continues to be a driving force behind innovation in diabetes and obesity treatment.
Join the newsletter to receive news, updates, new products and freebies in your inbox.